China initiates production of AI-assisted personalized tumor vaccines, potentially treating millions of new cancer patients annually, leveraging AI for rapid tumor DNA analysis.
Catherine, Princess of Wales, completes the Three Peaks Challenge to support the Royal Marsden Cancer Charity, emphasizing the importance of holistic healthcare for cancer patients, drawing from her personal experience of cancer treatment and remission.
A London clinic run by Alastair Jessel is reportedly using a dangerous method to treat stage 4 cancer patients, involving sealing them naked in plastic bags and gassing them with chlorine dioxide, an industrial bleach. Jessel admits the treatment is "dangerous" and "rarely done."
A report on Melbourne's Cohealth reveals mismanagement and poor governance, not just funding shortages, led to the closure of three GP clinics. The organization, serving disadvantaged patients, faced systemic issues ignored for a decade, with management failing to heed clinician advice and the board showing a lack of diligence.
Taiwan's Ministry of Health and Welfare and the Financial Supervisory Commission are working to enable home-based chemotherapy for cancer patients, addressing insurance coverage issues to allow treatment outside hospitals by the second half of the year.
UN warns US sanctions on Cuba cause spike in infant mortality and child cancer deaths due to lack of medical supplies, despite US claims humanitarian aid is exempt.
Daraxonrasib, a new drug targeting the RAS gene, doubles survival time for pancreatic cancer patients compared to chemotherapy, also improving quality of life with fewer severe side effects.
The Princess of Wales visited The Christie hospital in Manchester to see its holistic cancer care. She congratulated Claire Lorente, 30, on completing chemotherapy and ringing the 'end of treatment' bell, praising her bravery and acknowledging the toll on families.
NHS England has approved mirvetuximab soravtansine (Elahere) for women with platinum-resistant ovarian cancer, marking the first new drug for this condition in over 20 years. The treatment, administered every three weeks, delayed cancer progression and prolonged survival by an average of four months in clinical trials.
An immunotherapy drug, durvalumab, combined with chemotherapy and radiotherapy, has shown promise in treating bladder cancer, potentially sparing patients radical surgery and preventing tumor recurrence. Results presented at a major cancer conference indicated an 85% success rate in a trial.
A new DNA test, Prosigna, can identify breast cancer patients who may not need chemotherapy, with a trial showing over two-thirds of participants could be treated with hormone therapy alone, yielding a 93.7% five-year survival rate.
A 72-year-old man in Taiwan with advanced bladder cancer has had his tumor significantly shrink and avoid full bladder removal thanks to a new treatment combining targeted therapy (EV) and immunotherapy. This approach shows an 80% efficacy rate, a major improvement over traditional methods.
The Li Ka Shing Foundation will subsidize liver cancer surgeries for 200 patients over three years, covering HK$210,000 of the HK$260,000 cost for histotripsy treatment, a non-invasive ultrasound procedure.
Yoo Hae-jin donates 100 million won to Asan Medical Center to support cancer patients
More than 400 cancer patients are set to benefit from Hong Kong health authorities’ decision to subsidise a leukaemia drug, and will go from paying up to HK$500,000 (US$63,800) a year for treatment to forking out just HK$240. The Hospital Authority said on Wednesday that it began subsidising the medication, Dasatinib, in April, with the government expected to set aside an additional HK$49 million in annual spending to help cover the cost. As part of the move, Dasatinib was reclassified from a...
NHS is rolling out a one-minute pembrolizumab (Keytruda) injection for cancer patients, potentially helping 14,000 people annually in England. The immunotherapy treatment reduces infusion time by up to 90% and staff preparation time by 44%, freeing up vital NHS appointments. The jab works against lung, breast, head and neck, and cervical cancers, and is administered every three or six weeks depending on cancer type.
A 24-year-old cancer patient in Foshan, China, sparked a viral relay of kindness after ordering companionship through a food delivery app on April 15. Little Li, battling rare blood cancer, asked a rider to sit by her bedside for two hours, highlighting her loneliness during treatment with her father working away to fund her care.
Dr Mohsen Ali, a doctor whose licence was withdrawn in 2015, ran an unregistered clinic from a squalid Leicester council house in 2018, charging two cancer patients up to £15,000 for bogus treatments including intravenous garlic oil and vitamin C. The MPTS tribunal found Ali dishonest, telling patients the NHS was killing them and claiming a 90% cure rate. One patient with terminal ovarian cancer died shortly after stopping his treatment. Ali did not attend the tribunal.
Clinical trials presented at the SGO 2026 meeting indicate that the drugs relacorilant and pembrolizumab can significantly improve survival outcomes for patients with platinum-resistant ovarian cancer.
The NHS is expanding genetic testing for cancer patients to include a fifth DPYD gene variant, more prevalent in Black and minority ethnic individuals, aiming to prevent severe chemotherapy side-effects and fatal reactions.
